Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Now the shortages of Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound are over. The FDA determined in December and February, respectively, that the companies could meet demand.

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...

If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate.

Zepbound joins the GLP-1 ranks for weight loss with Wegovy and Saxenda. Tirzepatide is the main ingredient in Zepbound, approved label for weight management, and Mounjaro, the brand name approved ...

Since Zepbound was approved for weight loss in late 2023, it appeared to have an advantage over Wegovy. Patients taking the ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

She cycled through various formulations of the blockbuster therapies semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (sold as Zepbound for weight loss), finding some ...